Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Short-term Investments (2020 - 2024)

Cytek Biosciences filings provide 4 years of Short-term Investments readings, the most recent being $29000.0 for Q4 2024.

  • On a quarterly basis, Short-term Investments fell 91.24% to $29000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $29000.0, a 91.24% decrease, with the full-year FY2024 number at $29000.0, down 91.24% from a year prior.
  • Short-term Investments hit $29000.0 in Q4 2024 for Cytek Biosciences, down from $30816.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $2.9 million in Q1 2023 to a low of $29000.0 in Q4 2024.
  • Median Short-term Investments over the past 4 years was $365500.0 (2023), compared with a mean of $940727.0.
  • The widest YoY moves for Short-term Investments: up 86.29% in 2024, down 91.24% in 2024.
  • Cytek Biosciences' Short-term Investments stood at $888000.0 in 2020, then skyrocketed by 226.46% to $2.9 million in 2022, then tumbled by 88.58% to $331000.0 in 2023, then tumbled by 91.24% to $29000.0 in 2024.
  • The last three reported values for Short-term Investments were $29000.0 (Q4 2024), $30816.0 (Q3 2024), and $30000.0 (Q2 2024) per Business Quant data.